Company: BIAF
Filing Date: 2025-08-14
Form Type: 8-K
Source: 0001641172-25-024172
Chunk: 1

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-08-14
Form: 8-K
Item: Item 1.01
Chunk 1
---
,
pursuant to that certain placement agency agreement, dated as of August 13, 2025, between the Company and WallachBeth (the “ Placement
Agency Agreement”). Pursuant to the Placement Agency Agreement, the Company agreed to pay WallachBeth a total cash fee equal to
7.5% of the aggregate purchase price paid by the Purchasers in the Private Placement. The Company also agreed to reimburse WallachBeth
for all reasonable and out-of-pocket expenses incurred in connection with WallachBeth’s engagement in an amount not to exceed $65,000.
In addition, the Company agreed to issue to WallachBeth or its designees warrants (the “ Placement Agent Warrants”) to purchase
up to an aggregate of 129,130 shares of the Company’s Common Stock at an exercise price equal to $0.352 per share. The Placement
Agent Warrants are exercisable immediately upon issuance and have a term of exercise equal to five years from the date of issuance.

The
Placement Agency Agreement and the Purchase Agreement contain customary representations and warranties, agreements and obligations, conditions
to closing and termination provisions. The foregoing descriptions of terms and conditions of the Placement Agency Agreement, the Purchase
Agreement, the Warrants, the Registration Rights Agreement, and the Placement Agent Warrants do not purport to be complete and are qualified
in their entirety by the full text of the form of the Placement Agency Agreement, form of Purchase Agreement, the form of Warrant, the
form of Placement Agent Warrant, and the form of Registration Rights Agreement, which are attached hereto as Exhibits 1.1, 10.1, 4.1
4.2, and 10.2, respectively.

  -2-  

Warrant
Inducement Transaction

On
August 13, 2025, the Company entered into a warrant inducement agreement (the “ Warrant Inducement Agreement”) with the holder
(the “ Holder”) of a warrant to purchase 450,000 shares of Common Stock originally issued on August 5, 2024, with a current
exercise price of $1.25 per share (the “ August 2024 Warrant”) and a warrant to purchase 650,000 shares of Common Stock originally
issued on October 21, 2024 with a current exercise price of $1.50 per share (the “ October 2024 Warrant” and together with
the August 2024 Warrant, the “ Existing